Business / Finance

RSS

MedQuist Holdings prices initial public offering of common stock at $8.00 per share

MedQuist Holdings Inc., formerly CBaySystems Holdings Limited, a leading provider of integrated clinical documentation solutions for the U.S. Healthcare system, today announced the pricing of its U.S. initial public offering of 4,500,000 shares of its common stock at a price to the public of $8.00 per share.

4 Feb 2011

Incisive Surgical, Innocutis sign marketing agreement for INSORB Absorbable Skin Stapler

Innocutis Medical, a dermatology company focused on novel surgical devices and specialty pharmaceuticals, is pleased to announce an exclusive marketing agreement with Incisive Surgical, for the sales and marketing rights within the dermatology market for the patented INSORB Absorbable Skin Stapler, a revolutionary new modality for skin closure.

4 Feb 2011

BG Medicine prices initial public offering of 5,000,000 shares of common stock

BG Medicine today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price of $7.00 per share, before underwriting discounts and commissions. All shares are being sold by the Company.

4 Feb 2011

Accelerated completes acquisition of SPTRS, Burkam

Gryphon Investors announced today that its outpatient physical therapy platform company, Accelerated Rehabilitation Centers, has completed the acquisition of two physical therapy companies - Wisconsin based Sports Physical Therapy & Rehab Specialists and Ohio based Burkam & Associates.

4 Feb 2011

DaVita enters definitive agreement to acquire DSI Renal for $690 million

DaVita, announced that it has entered into a definitive agreement to acquire DSI Renal, for approximately $690 million, subject to adjustments. The company expects to close the transaction in the second or third quarter of this year.

4 Feb 2011

Precise Biometrics 2010 group's net sales decrease to SEK 44.9 million

Precise Biometrics AB, Year-end report for the period January - December 2010

4 Feb 2011

Merck reports GAAP net income of $861 million for 2010

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses.

4 Feb 2011

Aceto second quarter net sales increase 20.8% to $85.7 million

Aceto Corporation, a global leader in the sourcing, quality assurance, regulatory support, marketing and distribution of pharmaceuticals, nutraceuticals, specialty chemicals and crop protection products, today announced results of operations for its fiscal 2011 second quarter ended December 31, 2010.

4 Feb 2011

Sirona first quarter revenue increases 9.7% to $235.6 million

Sirona, the dental technology leader, today announced its financial results for the quarter ended December 31, 2010.

4 Feb 2011

Cord Blood America signs second Supply Agreement with premier cell and tissue bank

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that it has signed a Supply Agreement with a premier national and international cell and tissue bank to provide placenta, umbilical cord blood and whole umbilical cord collection services for research purposes.

4 Feb 2011

Prognosis brings EHR success to providers across the country

Prognosis Health Information Systems is making good on its mission of bringing electronic health records success to providers across the country.

4 Feb 2011

CAB expands offerings to EMS Transport business

CAB Receivables Management, a leader in creating cash flow performance solutions for specific industries, has expanded its offerings to the EMS Transport business.

4 Feb 2011

AMRI's Burlington facility granted AIFA approval to manufacture octreotide

AMRI announced today that it has received approval from the Italian Medicines Agency (AIFA) for its facility in Burlington, MA to manufacture the commercial drug product octreotide for a customer in the European Union (EU).

4 Feb 2011

Pacira prices initial public offering at $7.00 per share

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions.

4 Feb 2011

Grubb & Ellis Healthcare announces acquisition of Columbia Long-Term Acute Care Hospital

Grubb & Ellis Healthcare REIT II, Inc. today announced that it has acquired Columbia Long-Term Acute Care Hospital, a single-story, 31,000-square-foot, Class A single-tenant medical facility in Columbia, midway between Kansas City and St. Louis. The acquisition closed on Jan. 31.

3 Feb 2011

ZIOPHARM prices underwritten public offering of 9,600,000 shares of common stock

ZIOPHARM Oncology, today announced the pricing of an underwritten public offering of 9,600,000 shares of its common stock at a price to the public of $5.75 per share.

3 Feb 2011

NCR fourth-quarter revenue increases 5% to $1.4 billion

NCR Corporation reported financial results today for the three months ended December 31, 2010. Reported revenue of $1.4 billion increased 5 percent from the fourth quarter of 2009 on both an actual and constant currency basis.

3 Feb 2011

Repros prices public offering of 2,760,000 shares of common stock

Repros Therapeutics today announced the pricing of its public offering of 690,000 units, consisting of 2,760,000 shares of its common stock, Series A Warrants to purchase 2,070,000 shares of common stock and Series B Warrants to purchase 1,690,500 shares of its common stock, at a price per unit of $17.15.

3 Feb 2011

Nitto Denko announces acquisition of Avecia Biotechnology

Japan's leading diversified materials manufacturer, Nitto Denko Corporation, today announced that it has acquired Avecia Biotechnology, Inc. through Nitto Americas, Inc., a wholly owned subsidiary in Teaneck, New Jersey.

3 Feb 2011

Genmab reports GBP 9 million net sales for Arzerra in fourth quarter 2010

Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the fourth quarter of 2010 were GBP 9 million (approximately DKK 77 million).

3 Feb 2011